Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Comparative Study of Regional Nerve Blocks in Primary Cleft Palate Repair Primary endpoint(s) modified Children's National Research InstituteNot applicable NCT07892963
  2. Notable: Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study Enrolling by invitation only Hospital General Universitario de CastellónNot specified NCT07917988
  3. Notable: Multi-Strain Probiotic Supplementation (Hexbio®) in Malaysian · Drug-Resistant Epilepsy (ProbE) Primary endpoint(s) modified National University of MalaysiaNot applicable NCT07100743
  4. Notable: SBU-RESET · RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors Primary endpoint(s) modified Barbara NemesureNot applicable NCT07161713
  5. Notable: Motor Control Exercises With and Without Pressure Biofeedback in Recurrent Low Back Pain (MCE) Primary endpoint(s) modified University of Management and Technology LahoreNot applicable NCT07892079
  6. Notable: Short-Term Safety and Performance of a Wound Dressing Evaluation Primary endpoint(s) modified Sebastian ProbstNot applicable NCT07576322
  7. Notable: Imagery Rescripting as a Treatment for Early Psychosis Primary endpoint(s) modified Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Not applicable NCT06539780
  8. Notable: Virtual Reality Application and Progressive Relaxation Exercise Primary endpoint(s) modified Cukurova UniversityNot applicable NCT06896955
  9. Notable: FLASH Pilot Phase 1 Safety Study Primary endpoint(s) modified Lesley A. JarvisNot applicable NCT07608549
  10. Notable: Mobile Health Education to Enhance Self-management and Reduce Dose Delays for Breast Cancer Patients Receiving First-Time Chemotherapy: Randomized Controlled Trial Results posted: Nov 16, 2026 Taipei Medical University Shuang Ho HospitalNot applicable NCT06791603
  11. Notable: Elderly Patients, Does Goal-directed Fluid Management Using the Carotid Corrected Flow Time (CC-FT) Index, Compared to Routine Fluid Management, Affect the Occurrence of Post-induction Hypotension? Primary endpoint(s) modified Zhihong LUNot applicable NCT07925918
  12. Notable: Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength Primary endpoint(s) modified Hospital Clinic of BarcelonaNot applicable NCT07237867
  13. Notable: Virtual Reality-based Rehabilitation for Traumatic Hand and Wrist Injuries Primary endpoint(s) modified University of MalagaNot applicable NCT07633769
  14. Notable: Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy Device Enrollment increased: 60 → 90 participants National Health Research Institutes, TaiwanNot applicable NCT07764107
  15. Notable: Citicoline Eye Drops 2% on Visual Field Preservation · Open Angle Glaucoma Primary and study completion dates pushed to Jul 1, 2029 Omikron Italia S.r.l.Phase 3 NCT05710198
  16. Notable: Zasocitinib in Children and Teenagers With Plaque Psoriasis Primary and study completion pushed from Jan 24, 2033 to Jul 3, 2034 TakedaPhase 3 NCT07250802
  17. Notable: TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone · Recurrent Glioblastoma Primary completion pushed from Jul 2027 to Jul 2028 Telix Pharmaceuticals (Innovations) Pty LimitedPhase 3 NCT07100730
  18. Notable: Patients With Primary Vitreoretinal Lymphoma Primary and study completion pushed from Dec 2026 to Dec 2029 Aldeyra Therapeutics, Inc.Phase 3 NCT07402876
  19. Notable: Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules · Advanced or Unresectable Alveolar Soft Part Sarcoma Primary completion pushed from Nov 2027 to Dec 2028 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2 NCT07548177
  20. Notable: OPT101 · Type 1 Diabetes Mellitus Primary completion pushed from May 31, 2026 to May 31, 2027 Op-T LLCPhase 2 NCT06964087
  21. Notable: Intrathecally Administered Gene Therapy AMT-162 · SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) Primary completion pushed from Sep 30, 2026 to Dec 30, 2030 UniQure Biopharma B.V.Phase 1/2 NCT06100276
  22. Notable: Relacorilant in Combination With Different Treatment Regimens · Gynecological Cancers Primary completion pushed from Aug 2026 to Dec 2027 Corcept TherapeuticsPhase 2 NCT06906341
  23. Notable: NHWD-870 HCl in Adults and · Advanced NUT Cancer Primary completion pushed from Jun 30, 2025 to Mar 30, 2027 Zhejiang Wenda Pharma Technology LTD.Phase 2 NCT06527300
  24. Notable: Ablation of Arteries · Type 2 Diabetes Mellitus and Its Comorbidities Primary completion pushed from Jan 2025 to Jun 2027 Neurotronic, Inc.Phase 1 NCT05369065
  25. Notable: Arterial Ablation · Type 2 Diabetes Mellitus and Its Comorbidities Primary completion pushed from Jan 2025 to May 2027 Neurotronic, Inc.Phase 1 NCT05363761